Is Alpelisib a suitable targeted therapy for lung cancer patients?

Alpelisib (Alpelisib) is an inhibitor that targets the PI3Kα isoform, mainly targeting PIK3CA gene mutations. This mutation is common in certain types of breast cancer, especially hormone receptor-positive, HER2-negative breast cancer. Apelvis inhibits the proliferation and survival of tumor cells by selectively inhibiting the p110α isoform in the PI3K pathway. It is currently approved by the U.S. FDA to treat the specific types of breast cancer mentioned above.

In patients with non-small cell lung cancer (NSCLC), PIK3CA mutations are relatively rare, occurring in approximately 1%-3% of patients. Although some studies have pointed out that abnormal activation of the PIK3CA pathway may exist in certain lung cancer subgroups (such as adenocarcinoma or patients who have developed drug resistance after receiving EGFR-TKI treatment), there are currently no large-scale clinical trials that have confirmed the exact efficacy of apelvis in lung cancer patients. Therefore, in clinical practice, apelvis is not part of the standard treatment regimen for lung cancer.

Currently common targets for lung cancer patients includeEGFR, ALK, ROS1, MET, RET, KRAS G12C etc. For these mutation types, there are a variety of mature targeted drugs, such as Osimertinib (Osimertinib), Alectinib (Alectinib), etc. The PIK3CA mutation targeted by Apelvis is not the main driver mutation of lung cancer, so its clinical use in the treatment of lung cancer is still in the exploratory stage, and more clinical evidence is still needed to support its efficacy and safety.

Although apelvis is not currently widely used in the treatment of lung cancer, if clear PIK3CA is detected in individual lung cancer patientsWhen there is a mutation and no other target is available, Apelvis may be used as a "target-directed" personalized treatment attempt. However, such drug recommendations must be evaluated by professional oncologists and carried out in clinical trials or under strict monitoring whenever possible. With the development of precision medicine, whether apelvis will be included in the treatment plan for specific lung cancer subtypes in the future still needs to be verified by more research data.

Reference materials:https://www.drugs.com/